Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Floor J Backes

Showing results (71-80 of 110) with videos related to

Pageof 11
Sort By:
Molecular Cancer Therapeutics|September 20, 2019
ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2<sup>-/-</sup> Ovarian Cancer CellsLu Liu, Shurui Cai, Chunhua Han, et al.
Gynecologic Oncology|June 5, 2024
Retraction notice to "Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer" [Gynecologic Oncology 183 (2024) 78-84]Courtney J Riedinger, David A Barrington, Christa I Nagel, et al.
Gynecologic Oncology|March 30, 2024
RETRACTED: Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancerCourtney J Riedinger, David A Barrington, Christa I Nagel, et al.
American Journal of Obstetrics and Gynecology|December 27, 2022
Postoperative venous thromboembolism risk stratification in patients with uterine cancerVincent M Wagner, Rachael N Piver, Monica D Levine, et al.
Gynecologic Oncology Reports|March 13, 2023
Use of the Khorana score to predict venous thromboembolism in patients undergoing chemotherapy for uterine cancerRachael N Piver, Vincent M Wagner, Monica D Levine, et al.
Gynecologic Oncology|December 31, 2021
Who will be readmitted? Evaluation of the laparoscopic hysterectomy readmission score in a gynecologic oncology population undergoing robotic-assisted hysterectomyMichelle D S Lightfoot, Ashley S Felix, Erin E Bishop, et al.
Gynecologic Oncology|July 17, 2021
Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal CancerFloor J Backes, Lai Wei, Min Chen, et al.
Gynecologic Oncology|April 27, 2016
A pilot study of topical imiquimod therapy for the treatment of recurrent extramammary Paget's diseaseRenee A Cowan, Destin R Black, Lien N Hoang, et al.
BMC Genomics|April 1, 2017
Sparse feature selection for classification and prediction of metastasis in endometrial cancerMehmet Eren Ahsen, Todd P Boren, Nitin K Singh, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 13, 2015
Evaluation of the Hematologic Safety of Same Day Versus Standard Administration (24- to 72-Hour Delay) of Pegfilgrastim in Gynecology Oncology Patients Undergoing Cytotoxic ChemotherapyCaroline C Billingsley, Samuel N Jacobson, Sarah M Crafton, et al.
Pageof 11

Showing results (71-80 of 110) with videos related to

Sort By:
Pageof 11
Molecular Cancer Therapeutics|September 20, 2019
ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2<sup>-/-</sup> Ovarian Cancer CellsLu Liu, Shurui Cai, Chunhua Han, et al.
Gynecologic Oncology|June 5, 2024
Retraction notice to "Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer" [Gynecologic Oncology 183 (2024) 78-84]Courtney J Riedinger, David A Barrington, Christa I Nagel, et al.
Gynecologic Oncology|March 30, 2024
RETRACTED: Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancerCourtney J Riedinger, David A Barrington, Christa I Nagel, et al.
American Journal of Obstetrics and Gynecology|December 27, 2022
Postoperative venous thromboembolism risk stratification in patients with uterine cancerVincent M Wagner, Rachael N Piver, Monica D Levine, et al.
Gynecologic Oncology Reports|March 13, 2023
Use of the Khorana score to predict venous thromboembolism in patients undergoing chemotherapy for uterine cancerRachael N Piver, Vincent M Wagner, Monica D Levine, et al.
Gynecologic Oncology|December 31, 2021
Who will be readmitted? Evaluation of the laparoscopic hysterectomy readmission score in a gynecologic oncology population undergoing robotic-assisted hysterectomyMichelle D S Lightfoot, Ashley S Felix, Erin E Bishop, et al.
Gynecologic Oncology|July 17, 2021
Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal CancerFloor J Backes, Lai Wei, Min Chen, et al.
Gynecologic Oncology|April 27, 2016
A pilot study of topical imiquimod therapy for the treatment of recurrent extramammary Paget's diseaseRenee A Cowan, Destin R Black, Lien N Hoang, et al.
BMC Genomics|April 1, 2017
Sparse feature selection for classification and prediction of metastasis in endometrial cancerMehmet Eren Ahsen, Todd P Boren, Nitin K Singh, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 13, 2015
Evaluation of the Hematologic Safety of Same Day Versus Standard Administration (24- to 72-Hour Delay) of Pegfilgrastim in Gynecology Oncology Patients Undergoing Cytotoxic ChemotherapyCaroline C Billingsley, Samuel N Jacobson, Sarah M Crafton, et al.
Pageof 11